# Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

> **NCT00374868** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 59 (actual)

## Conditions studied

- Urologic Neoplasms

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00374868
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2010-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00374868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00374868, "Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00374868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*